Femasys Inc 8-K, filed Oct 20, 2022
Femasys Inc (FEMY)
8-K
2022-10-20
For: 2022-10-20
View Original
Added on
April 06, 2026
About this 8-K
Femasys Inc filed this 8-K on October 20, 2022.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 20, 2022
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(770 ) 500-3910
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instructions A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 7.01 |
Regulation FD Disclosure
|
On October 20, 2022, Femasys Inc. (the “Company”) posted on its website an updated slide presentation, which is attached as Exhibit 99.1 to this Current
Report on Form 8-K and incorporated by reference herein. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.
The information furnished in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as may be
expressly set forth by specific reference in such filing.
The Company expressly disclaims any obligation to update or revise any of the information contained in the corporate presentation.
| Item 8.01 |
Other Events
|
On October 20, 2022, Femasys Inc. (the “Company”) announced a strategic update on its FemaSeed® pivotal trial design to expedite clinical program
advancement. A copy of the press release is being furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit
No.
|
Description
|
|
Femasys Inc. Corporate Presentation dated October 2022
|
|
|
Press Release of Femasys Inc. dated October 20, 2022.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Femasys Inc.
|
||
|
By:
|
/s/ Kathy Lee-Sepsick
|
|
|
Names: Kathy Lee-Sepsick
|
||
|
Title: Chief Executive Officer
|
||
Date: October 20, 2022
Exhibit 99.1
Exhibit 99.2
Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement
- Updated FemaSeed® LOCAL artificial insemination trial design focuses on male factor infertility in patient trial
recruitment, with a goal of achieving accelerated enrollment -
ATLANTA, October 20, 2022 -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product
candidates that include minimally invasive, in-office technologies for reproductive health, today announced an updated study design for its FemaSeed® pivotal trial, which will now focus on couples experiencing male factor infertility.
This update reflects a revised strategy to address this underserved population experiencing infertility with a goal of facilitating accelerated enrollment.
“Over 60 million couples worldwide face infertility and approximately half is due to male factor infertility,” said Kathy
Lee-Sepsick, founder, president and chief executive officer of Femasys. “This represents a dramatic increase in prevalence over the past 40 years and is often overlooked. FemaSeed reduces the journey for sperm to travel by delivering directly to
the fallopian tube where conception occurs, making it particularly suitable for male factor infertility. Our revised approach to the FemaSeed LOCAL pivotal trial allows us to focus on a condition where we believe that we can have the greatest
impact and aligns with our mission to provide accessible, cost-effective solutions to couples who are looking to conceive.”
Edward Evantash, M.D., chief medical officer of Femasys, added, “As result of the trial
redesign, Femasys will be comprehensively evaluating significantly fewer treatment cycles, allowing us to advance our clinical program more efficiently. Most importantly, we hope this will bring us even closer to being able to provide
FemaSeed as an alternative to couples, particularly those struggling with male factor infertility.”
The FemaSeed LOCAL de novo clinical trial is a prospective multi-center, unblinded study (NCT04968847)
requiring evaluation of up to 214 women undergoing 214 FemaSeed cycles due to male factor infertility. The primary endpoints of the study are to determine the effectiveness (pregnancy rate) and safety over a period of seven weeks post-FemaSeed
procedure. Study enrollment is expected to be completed in 2023.
About FemaSeed
FemaSeed features intrauterine directional delivery that deposits sperm locally and directly to the fallopian tube where conception occurs. As the first
and only approach, presenting significant advantages over existing artificial insemination solutions, it is intended to become a first-line treatment for infertility.
About Male Factor Infertility
Of all infertility cases, approximately 40–50% is reportedly due to male factor infertility, which represents a dramatic increase in prevalence over the
past 40 years.1,2 Sperm counts worldwide have declined by over 50% between 1973 and 2011, with an increasing proportion of men having sperm counts below the threshold to be deemed sub-fertile or infertile.3,4 Assisted forms of
reproductive treatment such as in-vitro fertilization (“IVF”) or intracytoplasmic sperm injection (“ICSI”) are both effective first-line treatments but are associated with significant costs (approximately $30,000 USD), are often not covered by
health insurance and may pose clinical risks..5
About Femasys
Femasys Inc. is a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive,
in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s product for fallopian tube
assessment by ultrasound, FemVue®, and FemCerv®, an endocervical tissue sampler are currently being marketed in the United States. Femasys is also advancing FemCath™, an intrauterine catheter for selective
evaluation of the fallopian tubes intended to be marketed alongside its other women-specific medical products in the physician’s office setting. To learn more, visit www.femasys.com or follow us on Twitter and LinkedIn.
References:
1Kumar N., et al. (2015) Trends of male factor
infertility, an important cause of infertility: A review of literature. J Hum Reprod Sci. 8(4): pp. 191-196. DOI: 10.4103/0974-1208.170370
2Ravitsky V., et al. (2019) The forgotten men:
rising rates of male infertility urgently require new approaches for its prevention, diagnosis and treatment. Biol Reprod,. 101(5), pp. 872-874. DOI: 10.1093/biolre/ioz161
3Zegers-Hochschild F., et al. (2009) International
Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology. Fertil Steril.
92: pp. 1520-4. DOI: 10.1016/j.fertnstert.2009.09.009
4Levine H., et al. (2017) Temporal trends in sperm
count: a systemic review and meta-regression analysis. Human Reproduction. Vol. 23, No. 6, pp. 646-659. DOI: 10.1093/humupd/dmx022
5American College of Obstetricians and Gynecologists. (2019) Infertility workup for the women’s health specialist. ACOG Committee Opinion No.
781. Obstet Gynecol. 133: e377-84.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking
statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although
not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict
and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ
include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness
of our product candidates and other positive results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products, technologies and business, including our implementation
thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 and other reports as filed with the SEC. Forward-looking statements contained in
this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com
Media
Karissa Cross, Ph.D.
LifeSci Communications
kcross@lifescicomms.com
Femasys Inc.
Investor Contact:
IR@femasys.com
Media Contact:
Media@femasys.com








































